Pfizer Other Non-Current Liabilities 2012-2026 | PFE
Pfizer other non-current liabilities from 2012 to 2026. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Pfizer other non-current liabilities for the quarter ending March 31, 2026 were $17.006B, a 20.81% decline year-over-year.
- Pfizer other non-current liabilities for 2024 were $20.262B, a 19.19% decline from 2023.
- Pfizer other non-current liabilities for 2023 were $25.073B, a 9.05% increase from 2022.
- Pfizer other non-current liabilities for 2022 were $22.992B, a 9.1% increase from 2021.
|
Pfizer Annual Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2024 | $20,262 |
| 2023 | $25,073 |
| 2022 | $22,992 |
| 2021 | $21,074 |
| 2020 | $18,229 |
| 2019 | $19,020 |
| 2018 | $20,587 |
| 2017 | $24,846 |
| 2016 | $10,337 |
| 2015 | $9,249 |
| 2014 | $9,236 |
| 2013 | $8,760 |
| 2012 | $11,432 |
| 2011 | $12,986 |
|
Pfizer Quarterly Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2025-09-30 | $17,006 |
| 2025-06-30 | $17,244 |
| 2025-03-31 | $19,021 |
| 2024-12-31 | $20,262 |
| 2024-09-30 | $21,474 |
| 2024-06-30 | $22,627 |
| 2024-03-31 | $23,725 |
| 2023-12-31 | $25,073 |
| 2023-09-30 | $22,341 |
| 2023-06-30 | $21,455 |
| 2023-03-31 | $22,869 |
| 2022-12-31 | $22,992 |
| 2022-09-30 | $21,940 |
| 2022-06-30 | $22,301 |
| 2022-03-31 | $22,082 |
| 2021-12-31 | $21,074 |
| 2021-09-30 | $20,537 |
| 2021-06-30 | $19,487 |
| 2021-03-31 | $18,436 |
| 2020-12-31 | $18,229 |
| 2020-09-30 | $18,571 |
| 2020-06-30 | $18,280 |
| 2020-03-31 | $19,024 |
| 2019-12-31 | $19,020 |
| 2019-09-30 | $18,885 |
| 2019-06-30 | $18,604 |
| 2019-03-31 | $21,058 |
| 2018-12-31 | $20,587 |
| 2018-09-30 | $21,656 |
| 2018-06-30 | $21,544 |
| 2018-03-31 | $22,249 |
| 2017-12-31 | $24,846 |
| 2017-09-30 | $10,692 |
| 2017-06-30 | $10,536 |
| 2017-03-31 | $10,945 |
| 2016-12-31 | $10,337 |
| 2016-09-30 | $10,826 |
| 2016-06-30 | $9,634 |
| 2016-03-31 | $9,233 |
| 2015-12-31 | $9,249 |
| 2015-09-30 | $9,439 |
| 2015-06-30 | $9,669 |
| 2015-03-31 | $9,937 |
| 2014-12-31 | $9,236 |
| 2014-09-30 | $8,196 |
| 2014-06-30 | $8,038 |
| 2014-03-31 | $8,200 |
| 2013-12-31 | $8,760 |
| 2013-09-30 | $11,539 |
| 2013-06-30 | $12,050 |
| 2013-03-31 | $11,899 |
| 2012-12-31 | $11,432 |
| 2012-09-30 | $11,272 |
| 2012-06-30 | $12,935 |
| 2012-03-31 | $12,103 |
| 2011-12-31 | $12,986 |
| 2011-09-30 | $13,139 |
| 2011-06-30 | $11,761 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |